Inspections, Compliance, Enforcement, and Criminal Investigations
Dairyland Milk Company 04-Dec-03
Department of Health and Human Services
Public Health Service
Los Angeles District
December 4, 2003
RETURN RECEIPT REQUESTED W/L 12-04
Brian C. Blevins
Dairyland Milk Company
3345 N. Fuqua Rd.
Stanfield, AZ 85272
Dear Mr. Blevins:
Our records reflect you are the owner of Dairyland Milk Company located at
3345 N. Fuqua Rd, Stanfield, AZ. An investigation of your dairy operation conducted
by our investigator on September 24 and 26, 2003, confirmed that you offered
animals for sale for slaughter as food which is in violation of Sections 402(a)(2)(C)(ii)
and 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (henceforth the Act).
A food is adulterated under Section 402(a)(2)(C)(ii) of the Act if it contains a new animal drug that is unsafe within the meaning of Section 512 of the Act. A food is further adulterated under Section 402(a)(4) of the Act if it has been held under conditions whereby it may have been rendered injurious to health.
On or about July 28, 2003, you sold a culled dairy cow identified by USDA Laboratory report 283622 for slaughter as human food. USDA analysis of tissue samples collected from that animal identified the presence of penicillin in the kidney at 12.85 parts per million (ppm) and in the liver at 0.07 ppm. A tolerance of 0.05 ppm has been established for residues of penicillin in the edible tissues of cattle [21 CFR 556.510].
Our investigation also found that you hold animals under improper conditions whereby diseased animals and/or medicated animals bearing potentially harmful drug residues are likely to enter the food supply. For example, you lack an adequate system for assuring that animals medicated by you have been withheld from slaughter for the appropriate periods of time to permit depletion of potentially hazardous residues of drugs from edible tissues. Foods from animals held under suchconditions are considered adulterated under the Act.
It was further determined that you are using drugs in a manner contrary to their approved labeling. Such extra-label use is not permitted, except by or on the lawful written or oral order of a licensed veterinarian within the context of a valid veterinarian-client-patient relationship, and otherwise in compliance with the limitations set forth for specific extra-label uses [21 CFR 530.10 and 530.11]. Your use of drugs in any manner other than as labeled causes those drugs to be adulterated under Section 501 (a)(5) of the Act because there is no approval for such use as required by Section 512 (a)(1)(B) of the Act.
You are adulterating intramamary infusion tubes, such as [redacted] that you use on dairy cattle in a manner contrary to the approved labeling. The labeled withdrawal time is 10 days. Your shipment of an animal after 6 days is not in agreement with the approved labeling.
The above is not intended to be an all-inclusive list of violations. As a producer of animals, which are offered for use as food, you are responsible for assuring that your overall operations and the food you distribute are in compliance with the law.
Please note that it is not necessary for you to personally ship an adulterated animal in interstate commerce to be responsible for a violation of the Act. The fact that you caused the adulteration of an animal that was sold to a slaughterhouse which ships in interstate commerce is sufficient to hold you responsible for a violation of the Act.
You should take prompt action to correct the above violations and to assure that the procedures you have established will prevent their recurrence. Failure to do so may result in regulatory action, such as injunction, without further notice. This letter constitutes official notification under the law and provides you an opportunity to correct the violations.
Please advise this office in writing within fifteen (15) working days of receipt of this letter of the steps you have taken to bring your dairy into compliance with the law. Your response should include each step that has been taken to correct the violations and prevent their recurrence. If corrective action cannot be completed within fifteen (15) working days, state the reason for the delay and the time within which such corrections will be made. If you have any questions or need clarifications regarding this letter prior to your written response, you may contact Barbara Rincon, Compliance Officer at telephone number (949) 608-4439.
Your written response should be directed to:
Acting Director, Compliance Branch
U.S. Food and Drug Administration
Irvine, CA 92612
Aloha E. Cruse